Abeona Therapeutics (ABEO) Given a $36.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $36.00 price target on Abeona Therapeutics (NASDAQ:ABEO) in a research note released on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

ABEO has been the topic of several other research reports. Maxim Group restated a buy rating and set a $35.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, February 7th. HC Wainwright set a $30.00 price target on shares of Abeona Therapeutics and gave the company a buy rating in a research report on Thursday, February 8th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a sell rating to a hold rating in a research report on Monday. ValuEngine upgraded shares of Abeona Therapeutics from a sell rating to a hold rating in a research report on Friday, February 2nd. Finally, BidaskClub upgraded shares of Abeona Therapeutics from a sell rating to a hold rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $28.50.

ABEO stock opened at $16.53 on Tuesday. The firm has a market cap of $892.89 million, a P/E ratio of -25.04 and a beta of 1.27. Abeona Therapeutics has a one year low of $4.55 and a one year high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. The company had revenue of $2.60 million for the quarter, compared to analyst estimates of $0.27 million. Abeona Therapeutics had a negative net margin of 939.83% and a negative return on equity of 23.57%. equities analysts expect that Abeona Therapeutics will post -0.73 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in shares of Abeona Therapeutics by 89.8% in the fourth quarter. Bank of New York Mellon Corp now owns 195,474 shares of the biopharmaceutical company’s stock valued at $3,097,000 after purchasing an additional 92,465 shares during the period. Virtus Fund Advisers LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $346,000. EAM Investors LLC grew its position in shares of Abeona Therapeutics by 50.3% in the fourth quarter. EAM Investors LLC now owns 221,175 shares of the biopharmaceutical company’s stock valued at $3,506,000 after purchasing an additional 74,002 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $163,000. Finally, Virtu Financial LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $246,000. Institutional investors and hedge funds own 68.62% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply